当前位置: 首页 » 资讯 » 行业动态 » 正文

NVP 231研究进展

发布日期：2017-11-02   浏览次数：0
核心提示：a href=https://www.medchemexpress.com/NVP-231.htmlNVP 231/a产品描述：NVP-231 is a potent, specific, and reversible CerK
NVP 231产品描述：NVP-231 is a potent, specific, and reversible CerK inhibitor(IC50=12±2 nM) that competitively inhibits binding of ceramide to CerK.IC50 Value: 12±2 nM [1]Target: CERKin vitro: NVP-231 showed an IC50 value of 12 ± 2 nM and 90% inhibition at 100 nM in the radioassay. NVP-231 did not compete with ATP but rather with ceramide, displaying an inhibition constant (Ki) of 7.4 nM. Furthermore, inhibition by NVP-231 was instantaneous and fully reversible, implying that this compound does not covalently modify CerK. At 10 nM, NVP-231 inhibited C1P formation by >50%; at 100 nM, NVP-231 achieved complete inhibition. Thus the potency and efficacy of NVP-231 observed in cell culture are consistent with those found in vitro. It is noteworthy that, NVP-231 did not inhibit GlcCer and SM formation; rather, it increased these metabolites in correlation with compound concentration, demonstrating that NVP-231 does not act as a general inhibitor of ceramide metabolism [1]. The EC(50) of NVP-231 in thi


公司介绍：MedChemExpress(MCE)专注于各种抑制剂、激动剂、API及化合物库，总部位于美国新泽西，分别在瑞典和上海设有欧洲区子公司和亚洲区总代理，营销网点遍及全球20多个国家地区。MCE经过多年努力已成为全球生物活性小分子领域的一流供应商， 产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域，PI3K、MAPK等近千个细分靶点，超过4000个活性小分子化合物现货，以及GPCR、API、离子通道等超过20种不同类型的化合物库，同时提供从毫克到千克的专业定制合成服务。
MCE 对每批产品都进行严格的LCMS和NMR检验，其产品已被全球近万名客户广泛使用并发表大量文章、专利；
MCE 定期增加各领域热门抑制剂、激动剂，不断扩增已有化合物库，以满足最新的科研需求；
数千种产品在上海有充足备货，24-48小时内送达客户；
大量产品提供免费试用装；已为全球多个知名企业、院校构建各种定制型化合物库。

产品链接：www.medchemexpress.cn/nvp-231.html